Topic · Indication

Neuroendocrine tumours

Heterogeneous tumour group with hormone secretion (carcinoid syndrome, VIPomas, insulinomas). Somatostatin analogs are a central therapeutic pillar.

Peptides on this topic

1 peptide researched for this topic

Octreotide

Research other · 5 studies

Human RCT

Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours.

Relevant observations

Human RCTReduction in GH and IGF-1 levels in acromegaly patients documented in randomised trials
Human RCTReduction in flush-episode frequency and diarrhoea in carcinoid syndrome reported across multiple studies